Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity is for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Contact Hours.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AbbVie, Astellas, AstraZeneca, Exelixis, Inc., Ferring Pharmaceuticals, Inc., Genomic Health, Inc., Medivation, Inc., a Pfizer company, and Merck Sharp & Dohme Corp.
The Congress will focus on key clinical topics in the management of genitourinary malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as explore emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. The Congress continues to evolve and expand its coverage of some of the fastest moving areas in the management of genitourinary malignancies. To that end, there will be an expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that continue to alter the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of emerging biomarkers for these tumors, will be answered during expanded sessions on these topics.
This year’s New York GU™ meeting is not to be missed! The activity is sure to continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies.
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.
At the conclusion of this activity, participants should be better prepared to:
- Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision making in the management of GU malignancies
- Summarize recommendations that shape current strategies to care for patients with GU malignancies
- Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related side effects in caring for patients with GU malignancies
- Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage GU malignancies
- Apply emerging clinical concepts to support the management of GU malignancies in consideration of evolving treatment paradigms in the field
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University